Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22075488 | 0.86 | PGK1 (0.38) | PGK1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL9083244 | 0.79 | PGK1 (0.46) | PGK1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL18587109 | 0.76 | PTPN1 (0.35) | PGK1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL16791726 | 0.76 | PTGDR2 (0.50) | PGK1ALDH1A1CYP2C9PTGDR2 | |
| SCHEMBL19302890 | 0.74 | ALDH1A1 (0.47) | PGK1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6297687 | 0.72 | PGK1 (0.48) | PGK1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1838731 | 0.72 | PTGDR2 (0.41) | PGK1KDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL20360102 | 0.71 | PYCR1 (0.37) | PGK1ALDH1A1CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL29560750 | 0.71 | PYCR1 (0.37) | PGK1ALDH1A1CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL29202467 | 0.71 | KDM4E (0.41) | PGK1KDM4EALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200200765-A1 | BROAD SPECTRUM GPCR BINDING AGENTS | PROMEGA CORPORATION | 2020-06-25 | — | — | US | disclosed |
| WO-2020117954-A2 | BROAD SPECTRUM GPCR BINDING AGENTS | PROMEGA CORPORATION (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200200765-A1 | BROAD SPECTRUM GPCR BINDING AGENTS | GPR139, GPR4, GPR3 | PGK1 3294/4885KDM4E 4254/4885ALDH1A1 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.